Auranofin, a rheumatoid arthritis drug, has been validated to repurpose application to trigger apoptosis and necroptosis in auranofin-sensitive lung cancer cells, accompanied by suppressing the PI3K/AKT/mTOR pathway. This evidence concerns the gene AKT1 and lung carcinoma.